The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
|Videos|July 15, 2011
Dr. Schuchter on the Progression of Melanoma Care
Author(s)Lynn M. Schuchter, MD
Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years
Advertisement
Lynn M. Schuchter, MD, division chief of hematology-oncology at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia describes how treatment in melanoma has advanced over the past 25 years, starting with the first drugs approved for the disease and advancing into the modern era.
Advertisement
Related to this article
New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5